NASDAQ: SABSSab Biotherapeutics Inc Stock
$2.98-0.08 (-2.61%)
Updated Oct 2, 2026
SABS Price
$2.98
Fair Value Price
$0.07
Market Cap
$271.14M
52 Week Low
$2.06
52 Week High
$5.15
P/E
-4.66x
P/B
1.26x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$12.78M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.11
Operating Cash Flow
-$54M
Beta
0.77
Next Earnings
Nov 13, 2026
Ex-Dividend
N/A
Next Dividend
N/A
SABS Overview
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SABS's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
SABS
Ranked#377 of 461
Ranked#377 of 461
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.51 | A | |
| $8.54 | A | |
| $358.07 | A |
Be the first to know about important SABS news, forecast changes, insider trades & much more!
SABS News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SABS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SABS ($2.98) is overvalued by 3,915.68% relative to our estimate of its Fair Value price of $0.07 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
SABS ($2.98) is not significantly undervalued (3,915.68%) relative to our estimate of its Fair Value price of $0.07 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SABS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SABS due diligence checks available for Premium users.
Valuation
SABS fair value
Fair Value of SABS stock based on Discounted Cash Flow (DCF)
Price
$2.98
Fair Value
$0.07
Overvalued by
3,915.68%
SABS ($2.98) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SABS ($2.98) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SABS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SABS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.66x
Industry
12.21x
Market
49.66x
SABS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.26x
Industry
5.04x
SABS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SABS's financial health
Profit margin
Revenue
$0.0
Net Income
-$22.5M
Profit Margin
0%
SABS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$238.2M
Liabilities
$23.4M
Debt to equity
0.11
SABS's short-term assets ($107.94M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SABS's short-term assets ($107.94M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SABS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SABS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$9.8M
Investing
-$4.9M
Financing
$2.4M
SABS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SABS vs Biotech Stocks
Sab Biotherapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.